ACADACADIA Pharmaceuticals Inc.

$4B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$265M+9.3% YoY

Gross Profit

$244M92.2% margin

Operating Income

$32M12.2% margin

Net Income

$27M10.1% margin

EPS (Diluted)

$0.16

QoQ Revenue Growth

+8.3%

Cash Flow

Operating Cash Flow

$64M

Free Cash Flow

$162M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$403M

Stockholders' Equity

$822M

Cash & Equivalents

$254M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$265M	$242M	+9.3%
Gross Profit	$244M	$224M	+9.0%
Operating Income	$32M	$30M	+6.4%
Net Income	$27M	$33M	-20.1%

ACAD Q2 2025 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena